Concord Biotech Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges

Technical Trend Improvement Spurs Rating Upgrade

The most significant catalyst for the upgrade was the change in the technical grade, which moved from bearish to mildly bearish. This subtle improvement in technical momentum has been noted across several key indicators. The weekly Moving Average Convergence Divergence (MACD) remains bearish, but the monthly MACD is neutral, signalling a potential stabilisation in price momentum. Meanwhile, the Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, indicating neither overbought nor oversold conditions.

Bollinger Bands on both weekly and monthly timeframes have shifted to mildly bearish, suggesting reduced volatility and a possible consolidation phase. Daily moving averages remain bearish, but the weekly KST (Know Sure Thing) indicator is bearish while the monthly KST is neutral, further supporting a cautious technical outlook. Dow Theory analysis shows no clear trend weekly but mildly bearish monthly, while On-Balance Volume (OBV) is neutral weekly and bullish monthly, hinting at underlying buying interest despite price weakness.

These mixed but improving technical signals have encouraged analysts to revise the technical grade upwards, which played a pivotal role in the overall rating upgrade.

Financial Trend Remains Weak with Consecutive Negative Quarters

Despite the technical improvement, Concord Biotech’s financial trend continues to deteriorate. The company has reported negative results for three consecutive quarters, with Q3 FY25-26 showing a Profit Before Tax (PBT) excluding other income of ₹79.46 crores, down 15.9% compared to the previous four-quarter average. Net Profit After Tax (PAT) for the quarter stood at ₹66.90 crores, a decline of 17.4% over the same period.

Operating profit growth has been negative at an annualised rate of -0.34% over the last five years, signalling stagnation in core business profitability. Return on Capital Employed (ROCE) for the half-year is at a low 23.48%, while Return on Equity (ROE) remains relatively high at 17.7%, reflecting efficient capital utilisation but not enough to offset declining earnings. The company’s low debt-to-equity ratio, averaging zero, indicates a conservative capital structure, but this has not translated into growth or improved profitability.

Valuation Concerns Amidst Expensive Price Metrics

Concord Biotech’s valuation remains a key concern for investors. The stock trades at a Price to Book Value (P/BV) of 5.9, which is considered very expensive relative to its peers and historical averages. This premium valuation is difficult to justify given the company’s recent financial underperformance and negative profit growth of -3.5% over the past year.

Moreover, the stock’s price performance has been disappointing, with a one-year return of -37.19%, significantly underperforming the Sensex’s modest decline of -1.67% over the same period. Over the last month, the stock fell by 14.58%, compared to a 6.10% drop in the Sensex, and year-to-date returns are down 23.42%, well below the benchmark’s -13.04%.

The 52-week high of ₹2,149.90 contrasts sharply with the current price near ₹1,030, indicating a substantial correction and heightened volatility. The stock’s 52-week low is ₹1,008.75, close to today’s low of ₹1,008.75, suggesting limited downside room but also a lack of strong recovery momentum.

Quality Assessment: High Management Efficiency but Poor Growth

From a quality perspective, Concord Biotech exhibits mixed signals. The company benefits from high management efficiency, as reflected in its ROE of 19.17%, which is commendable in the pharmaceuticals and biotechnology sector. The promoter holding remains majority, providing stability in ownership and strategic direction.

However, the company’s long-term growth trajectory is disappointing. Operating profit has barely grown over five years, and recent quarterly results have been negative. This stagnation undermines the quality rating, as sustainable growth is critical for long-term shareholder value creation in this sector.

Technicals and Market Sentiment

Technically, the stock shows signs of stabilisation after a prolonged bearish phase. The mild improvement in technical indicators such as Bollinger Bands and OBV on monthly charts suggests that selling pressure may be easing. However, daily moving averages and weekly MACD remain bearish, indicating that any recovery is tentative and requires confirmation.

Market sentiment remains cautious, reflected in the stock’s underperformance relative to the broader market indices like the Sensex and BSE500 over multiple time horizons. The lack of a clear bullish trend in Dow Theory and mixed signals from momentum indicators imply that investors should remain vigilant.

Summary and Outlook

In summary, Concord Biotech Ltd’s investment rating upgrade from Strong Sell to Sell is primarily driven by a modest improvement in technical indicators, signalling a potential bottoming out of the stock price. However, the company’s financial performance remains weak, with declining profits, negative operating growth, and expensive valuation metrics that do not support a more optimistic rating.

Investors should weigh the improved technical signals against the persistent fundamental challenges. The stock’s underperformance relative to the Sensex and BSE500 indices over the past year and longer-term periods highlights the risks involved. While management efficiency and low leverage are positives, they have not translated into growth or value creation recently.

Given these factors, the Sell rating reflects a cautious stance, suggesting that investors may consider exiting or avoiding new positions until clearer signs of financial recovery and sustained technical strength emerge.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →